Ocular Oncology Focus Aura's lead program bel-sar AU-011 targets late-stage choroidal melanoma and early bladder cancer; this creates immediate sales opportunities with ocular oncology clinics, ophthalmic oncology networks, and dedicated urology/cancer centers to discuss investigator-initiated studies, clinical access programs, and early collaboration deals.

Growth Financing Signals A substantial 2026 financing and a new CEO signal readiness to scale commercialization; approach opportunities to discuss strategic partnerships, co-development or co-commercialization with larger oncology players, and to engage potential distribution or licensing arrangements across regions.

KOL Momentum Aura's active investor conferences and EAU congress participation indicate pathways to engage key opinion leaders; build a targeted outreach plan to secure KOL endorsements, site readiness, and patient referral networks that accelerate enrollment and adoption in ocular oncology and NMIBC.

Outsourcing Partners As a clinical-stage company, Aura will rely on contract manufacturing and CROs; identify CDMOs and clinical trial partners with ocular tumor therapy experience to support late-stage trials, regulatory filings, and scalable supply for potential launch.

Organ Preservation Value Aura emphasizes organ-sparing therapies, a compelling differentiator for payers and centers of excellence; develop value dossiers highlighting quality-of-life and functional-preservation benefits to support access, pricing strategies, and regional adoption in US and international markets.